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Introduction: Grapefruit juice (GFJ) is known to decrease the plasma 
concentrations of several drugs by inhibiting organic anion-transport-
ing polypeptide (OATP) 2B1. We aimed to determine the duration of 
the inhibitory effect of GFJ on OATP by comparison with the duration 
of the GFJ-mediated effects on cytochrome P450 (CYP) 3A4 activity.
Patients (or Materials) and Methods: Seven Japanese healthy sub-
jects were enrolled and administered celiprolol (Cel) and midazolam 
(Mdz), which are substrates of OATP2B1 and CYP3A4, respectively, 
on days 1, 3, and 7 (0, 48, and 144 hours after the ingestion of 
GFJ). On the control day, Cel (100 mg) and Mdz (15 μ g/kg) were 
orally administered with water. Three days later, all subjects drank 
GFJ (200 mL 3 times a day) for 3 days. On day 1, the same doses 
of the drugs were administered with GFJ. On days 3 and 7, the 
subjects were administered the same doses of the drugs with water. 
Pharmacokinetics and hemodynamic parameters of both drugs were 
evaluated on each day. The plasma concentrations of Cel and Mdz 
were determined by LC-MS/MS. The study protocol was approved 
by the ethics committee of Hamamatsu University School of Medicine 
and University of Shizuoka, and all participants provided written 
informed consent before the study was initiated.
Results: Plasma concentrations of Cel were lower on day 1 than 
on the control day. AUC0–8 and Cmax of Cel were significantly 
decreased on day 1, and the mean ratios of these values and the cor-
responding control-day values were 0.21 and 0.15, respectively. The 
Cmax and AUC0–8 returned to the corresponding control levels on 
days 3 and 7. In contrast, AUC0–8 of Mdz was higher on days 1 and 
3 than on the control day, with the mean ratios of the corresponding 
values and control-day value being 2.00 and 1.42, respectively. The 
AUC0–8 returned to the control level on day 7. Systolic and diastolic 
blood pressure or heart rate at 1 and 3 hours after administration of 
drugs did not changed by the intake of GFJ.
Conclusion: GFJ greatly reduced Cmax and AUC0–8 of Cel sug-
gesting that it strongly inhibited OATP2B1. However, the OATP2B1 
inhibition caused by GFJ dissipated faster than the GFJ-mediated 
alterations in CYP3A4 activity, which were sustained for at least 48 
hours. Our results are clinically relevant because many patients take 
OATP substrates daily, and knowing the duration of inhibition would 
help patient interactions.
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Introduction: The pivotal role of the organic cation transporter 
OCT2 for the renal excretion of cationic drugs raises the risk for 
drug–drug interactions in which 1 drug reduces OCT2-mediated 
elimination of a second drug. In vivo testing of drug–drug interac-
tions is time-consuming and costly. Therefore, additional strategies 
are needed to predict drug–drug interactions (DDIs). We used a large 
set of experimental data to develop a chemoinformatics-based model 
to predict OCT2-inhibition in silico.
Patients (or Materials) and Methods: A total of 125 frequently pre-
scribed drugs (inpatient prescriptions in Germany, > 4 mio. DDD 
each) were systematically screened for their inhibitory interaction 
with OCT2. As a test system, we used stably transfected HEK-
OCT2 cells and 2 prototypical OCT2 substrates, [3H]1-methyl-
4-phenylpyridinium ([3H]MPP+, 50µM) and [14C]metformin (1 
mM). The potential inhibitors were tested at 20 and 200 µM. The 
experimental data were used for chemoinformatic modeling to pre-
dict OCT2-inhibition in silico. We used CORINA version 3.4 for 
structure processing and MOSES Descriptors Community Edition 
version 1.0 to calculate descriptors and pharmacophores of the test 
compounds. Decision tree models were developed using Weka ver-
sion 3.6.
Results: At 20 µM, 11% and 46%, respectively, of the tested com-
pounds decreased OCT2-mediated uptake of [3H]MPP+ and [14C]
metformin by > 50%. The most potent inhibitors of MPP+ trans-
port via OCT2 were pantoprazole, doxepin, and clomipramine. 
Metformin uptake was most potently inhibited by trimipramine, 
trospium chloride, and doxepin. The respective IC50 values for inhi-
bition of OCT2-mediated metformin uptake were 0.34, 0.07, and 
0.50 µM. We generated a consensus decision tree model based on 
the experimental inhibition data. This model classified the test drugs 
correctly into inhibitors or noninhibitors with an overall accuracy of 
76%, a positive predictive value of 83%, and a negative predictive 
value of 89%.
Conclusion: Our decision tree model is able to predict OCT2 inhi-
bition in silico with high reliability. If clinical data are missing, the 
chemoinformatics-based model might be an additional tool for the 
prediction of potential drug–drug interactions. Our aim is the inte-
gration of the in silico model in a medication management system.
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Introduction: In the last years, a growing trend in antiepileptic drug 
(AED) use was observed, but few data concerning indication of use 
and drug interaction risk are available in general practice. The aims 
of this study were: to analyze the prevalence, incidence of use, and the 
prescribing pattern of newer and older AEDs; to assess the exposure 
to potential interactions between AEDs and other drugs in a general 
practice setting of Southern Italy.
Patients (or Materials) and Methods: We analyzed a population of 
almost 150,000 individuals living in Caserta and registered in 123 
general practitioners’ lists. Patients who received at least 1 AED pre-
scription during 2005–2011 were identified. The use of newer and 
older AEDs was calculated as 1-year prevalence and incidence; AEDs 
consumption was evaluated as defined daily dose (DDD)/10,000 
inhabitants/d. Clinically relevant interacting drugs were identified 
and the risk of drugs interactions was calculated as overlapping days 
between the exposition days of AEDs and interacting drugs.
Results: Prevalence of old AED use slightly increased from 10.7/1000 
inhabitants in 2005 to 13.0/1000 in 2011, while a strong increase 
of newer AED use was observed from 14.7/1000 to 22.3 until 2006, 
followed by a deep fall to 16.2/1000 inh in 2011. Among older AEDs, 
phenobarbital and valproate were the most widely used in 2011, 
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accounting for 21.2% and 16.2% of total AED consumption (DDD 
163.7 and 125.2, respectively). In the same year, oxcarbazepine and 
lamotrigine were the most used new AEDs (10.91% and 10.79% of 
total; DDD 84.1 and 83.2, respectively), while gabapentin and pre-
gabalin exhibited the higher incidence of use. The main indication of 
use was epileptic disorders for older AEDs and neuropathic pain for 
newer AEDs. A high number of patients treated with older AEDs, in 
particular carbamazepine, phenobarbital, and valproic acid, received 
coprescription at clinically relevant interaction risk. Among newer 
AEDs, lamotrigine showed a high annual rate of possible interaction.
Conclusion: Significant differences were shown in the prescribing 
pattern of newer and older medications: older AEDs were mainly 
used in the treatment of epileptic disorders, while newer compounds 
were also preferred for conditions other than epilepsy, in particular 
neuropathic pain. The fall in the use of newer AEDs during 2007 
agreed with revised reimbursement criteria for gabapentin and pre-
gabalin. The coprescription should be evaluated with caution and 
avoided if possible. Drugs at risk of interactions should be replaced 
with others having same indication of use.
Disclosure of Interest: None declared.
PP179—IDentIfIcatIon of Drug–Drug 
InteractIons through a DIgItal health 
servIce
S. Ussai1*; A. Casetta2; F. Pisa1; G. Trillò3; R. Petelin4;  
F. Barbone1,2; A. Degrassi4; and G. Giagnorio5
1Institute of Hygiene and Clinical Epidemiology, University 
Hospital of Udine; 2Dept. of Medical and Biological Sciences, 
University of Udine; 3Helicopter Emergency Medical Service 
Friuli-Venezia Giulia, Udine Hospital, Udine; 4R&D Department, 
Infostruttura Research Organization; and 5Dept. of Emergency 
and Disaster Medicine, Ass.2 ‘Isontina’, Gorizia, Italy
Introduction: Drug–drug interactions (DDIs) may have severe and 
life-threatening health consequences. To identify DDIs, a cloud-based 
surveillance has been implemented in a network of 12 pharmacies, 
1 general hospital, and 24 general physicians of the ASS2 Health 
District, North East Italy.
Patients (or Materials) and Methods: DDIs were identified through 
a fully automated, closed loop system that records and updates, by 
specifically designed software interfaces loaded on Information and 
Communication Technology (ICT) programs of the network, all the 
drugs taken during therapy cycle/s. Each patient, agreeing to partici-
pate, was linked through her/his tax code to all prescription/OTC 
drugs managed from October 2012 to March 2013, generating a 
personal pharmacologic profile. Data on age, sex, and comorbidity 
were collected in the beginning of the study. DDIs were identified and 
classified according to Mario Negri Institute definition in 3 severity 
groups: low (no suspension or change in therapy required), moderate 
(change in treatment, additional therapy or hospitalization required), 
and high (potentially fatal).
Results: A total of 369 patients (58.3% women) were included. 
About 30% shown 1 comorbidity and 11.8% 2 or more. 
Cardiovascular diseases (22.7%) represented the most frequent 
comorbidity, followed by musculoskeletal pathology (13.6%), dia-
betes (8.6%), cancer (5.1%), and depression (4.8%). The Charlson 
Comorbidity Index was 0 in 65.2%, 1 in 25.7%, 2 in 7.0% and 3 to 
4 in 2.1%. A total of 67 patients (mean age, 72 [12] years; 52.2% 
women) had at least 1 DDI. About 50% (N = 33) had up to 2 DDIs, 
25% from 3 to 7 DDIs and 25% ≥ 8 (from 9–74 DDIs per person). 
A total of 501 DDIs were identified: the severity was low in 35.5%, 
moderate in 59.7% and high in 4.8%. The top 10 drugs involved in 
DDI were: acetylsalicylic acid (ASA), hydrochlorothiazide, ibupro-
fen, diclofenac, digoxin, nebivolol, pantoprazole, ramipril, furosem-
ide, and nimesulide. DDIs occured more frequently with ASA and 
hydrochlorothiazide (6.2%), hydrochlorothiazide and pantoprazole 
(4.6%), ASA and ibuprofen (3.4%), ASA and nebivolol (3.4%), and 
ASA and nitroglycerin (3.2%). About 50% of DDIs involving ASA, 
hydrochlorothiazide, and ibuprofen were of low severity and another 
50% of moderate severity. For diclofenac, low severity DDIs were 
27.6% and 72.4% moderate while for digoxin 75.7% were moder-
ate and 24.3% high.
Conclusion: ICT technologies are useful to timely identify DDIs of 
clinical relevance and the drugs most frequently involved.
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Introduction: Due to its high solubility and low permeability, nado-
lol, a nonselective β -blocker, is categorized as a class III drug in a 
Biopharmaceutics Classification System, and therefore nadolol may 
require active influx transporters to permeate gut wall mucosa during 
intestinal absorption. Members of the organic anion transporting 
polypeptide (OATP) family such as OATP1A2 and OATP2B1 have 
previously been reported to be involved in intestinal absorption of 
several drugs. However, the molecular mechanism of nadolol uptake 
into enterocytes still remains unknown.
Patients (or Materials) and Methods: Human embryonic kidney 
(HEK) 293 cell lines stably expressing OATP1A2 or OATP2B1 were 
used to investigate whether nadolol is a substrate for these trans-
porters using [3H]nadolol. Epigallocatechin 3-gallate (EGCG), a 
flavonoid highly abundant in green tea, was used as an inhibitor of 
OATP1A2- and OATP2B1-mediated transport.
Results: No significant nadolol uptake was observed in 
OATP2B1-expressing cells. In contrast, the uptake of nadolol in 
OATP1A2-expressing cells was significantly greater than that in 
vector-transfected cells. OATP1A2-mediated nadolol uptake was 
saturable with Km and Vmax values of 84.3 (1.0) μ M and 332.8 
(125.5) pmol/min/mg protein, respectively. OATP1A2-mediated 
uptake of nadolol was inhibited in a concentration dependent man-
ner by EGCG with an IC50 value of 37.3 (5.9) μ M.
Conclusion: These data suggest that OATP1A2 is predominantly 
involved in the cellular uptake of nadolol, while the role of OATP2B1 
may be negligible. The inhibition of OATP1A2-mediated nadolol 
uptake might be involved in drug–drug and drug–food interactions 
with this β -blocker.
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